Amgen

Headlines · 2

1. Oct 20
   OpenAI acquires Orchestra Bio to add drug-development agents to Rosalind

   OpenAI said it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development, and will combine its team and technology with Rosalind, OpenAI's AI models and tools for life sciences research. Financial terms were not disclosed; Chinese outlets report Orchestra was founded in San Francisco in 2022 and had raised about $20 million from investors including a16z, 8VC and Insight Partners as of August 2025. OpenAI says Orchestra's agents are designed to track trials and flag affected timelines when something goes wrong, such as a failed production batch, and that Rosalind already counts Moderna and Novo Nordisk as customers. OpenAI frames the deal as a step toward agents that connect scientific findings with the studies, decisions and next steps needed to advance a potential medicine.

   OpenAI · 🔥 0
2. Oct 10
   OpenAI pricing page lists unannounced gpt-rosalind-discovery life sciences model

   TestingCatalog reported that OpenAI's API pricing page now lists an unannounced model, gpt-rosalind-discovery, under a "Life sciences models" section next to the already public gpt-rosalind-research, with identical pricing of $5 per million input tokens, $0.50 per million cached input tokens and $25 per million output tokens. There is still no blog post, help article or system card for it, and MIT Technology Review China said the model documentation pages return 404 errors, leaving pricing as the only published information. Outside observers guess from the "discovery" name that it targets drug discovery, but its purpose, its relationship to the research model and any real gains remain undisclosed.

   TestingCatalog · 🔥 0

Experience and discussion from the community

Share my Amgen experienceAsk about Amgen